Neil Shusterman

Summary

Country: USA

Publications

  1. ncbi Risk-benefit assessment of angiotensin II receptor antagonists
    Neil Shusterman
    University of Pennsylvania School of Medicine, Presbyterian Medical Center, 39th and Market Street, Philadelphia, PA 19104, USA
    Expert Opin Drug Saf 1:137-52. 2002

Detail Information

Publications1

  1. ncbi Risk-benefit assessment of angiotensin II receptor antagonists
    Neil Shusterman
    University of Pennsylvania School of Medicine, Presbyterian Medical Center, 39th and Market Street, Philadelphia, PA 19104, USA
    Expert Opin Drug Saf 1:137-52. 2002
    ..Overall, AIIRAs represent an important addition to the armamentarium of cardiovascular therapies with an excellent safety record and an emerging profile of utility in multiple cardiovascular conditions...